Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Mei Zheng und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China. Hauptthemen laut MEDLINE: Ceftazidime, Klebsiella pneumoniae, Drug Combinations, Azabicyclo Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Swiss National Science Foundation, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Objectives
The emergence and expansion of carbapenem-resistant Klebsiella pneumoniae infections is a concern due to the lack of ‘first-line’ antibiotic treatment options. The ceftazidime/avibactam is an important clinical treatment for carbapenem-resistant K. pneumoniae infections but there is an increasing number of cases of treatment failure and drug resistance. Therefore, a potential solution is combination therapies that result in synergistic activity against K. pneumoniae carbapenemase: producing K. pneumoniae (KPC-Kp) isolates and preventing the emergence of KPC mutants resistant to ceftazidime/avibactam are needed in lieu of novel antibiotics.
Methods
To evaluate their synergistic activity, antibiotic combinations were tested against 26 KPC-Kp strains. Antibiotic resistance profiles, molecular characteristics and virulence genes were investigated by susceptibility testing and whole-genome sequencing. Antibiotic synergy was evaluated by in vitro chequerboard experiments, time-killing curves and dose–response assays. The mouse thigh model was used to confirm antibiotic combination activities in vivo. Additionally, antibiotic combinations were evaluated for their ability to prevent the emergence of ceftazidime/avibactam resistant mutations of blaKPC.
Results
The combination of ceftazidime/avibactam plus meropenem showed remarkable synergistic activity against 26 strains and restored susceptibility to both the partnering antibiotics. The significant therapeutic effect of ceftazidime/avibactam combined with meropenem was also confirmed in the mouse model and bacterial loads in the thigh muscle of the combination groups were significantly reduced. Furthermore, ceftazidime/avibactam plus meropenem showed significant activity in preventing the occurrence of resistance mutations.
Conclusions
Our results indicated that the combination of ceftazidime/avibactam plus meropenem offers viable therapeutic alternatives in treating serious infections due to KPC-Kp.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China.
- Guangdong Laboratory for Lingnan Modern Agriculture, National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Gua…
- Service of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, 1211, Switzerland.
- Infectious Diseases Division, Federal University of Sao Paulo-UNIFESP, Escola Paulista de Medicina, São Paulo, Brazil.
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.
ORCID-Profile: Ana C Gales, Wan-Jiang Zhang, Jian Sun
Förderung
- Swiss National Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Geneva University Hospitals
Zitieren
APA
Zheng, M., Li, F. H., Liu, J., Li, W. J., Yin, R. X., Cai, D. T., Andrey, D. O., Zheng, S. L., Gales, A. C., Zhang, W. J., Sun, J., Liao, X. P., & Yu, Y. (2024). Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae074
Vancouver
Zheng M, Li FH, Liu J, Li WJ, Yin RX, Cai DT, et al. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae074
BibTeX
@article{Zheng2024,
author = {Zheng, Mei and Li, Fu-Hao and Liu, Juan and Li, Wen-Jie and Yin, Ruo-Xi and Cai, Da-Tong and Andrey, Diego O and Zheng, Si-Lin and Gales, Ana C and Zhang, Wan-Jiang and Sun, Jian and Liao, Xiao-Ping and Yu, Yang},
title = {Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae074}
}
EUVIMED